

Clinical Phase II Development of NT-101: An Innovative Topical Therapy for wet Age-Related Macular Degeneration

NexThera Co., Ltd.



OPHTHALMOLOGY		Phase 2
Product Type	rProtein	
Indication	Wet AMD (Age related-macular degeneration)	
Target	PEDF pathway (angiogenesis and neuroprotection)	
MoA(Mechanism of Action)	Multi-factorial targets, VEGF-independent mechanisms	
Competitiveness	• Non-invasive formulation (eye drop) Developed as an eye drop rather than an intravitreal injection, improving patient convenience and adherence. • VEGF-independent multi-target mechanism targeting PEDF to overcome anti-VEGF resistance and efficiently preserve vision via anti-angiogenesis and retinal neuroprotection.	
Development Stage	Phase 2	
Route of Administration	Ocular solution, Topical (Eye drop)	

Any unauthorized distribution or reproduction of this material is strictly prohibited.